HTML Microdata document

This HTML5 document contains 58 embedded RDF statements represented using HTML+Microdata notation.

The embedded RDF content will be recognized by any processor of HTML5 Microdata.

Namespace Prefixes

Prefix	IRI
n7	http://linked.opendata.cz/resource/drugbank/drug/DB00837/identifier/pubchem-substance/
n2	http://linked.opendata.cz/resource/drugbank/drug/
dcterms	http://purl.org/dc/terms/
n18	http://linked.opendata.cz/resource/drugbank/drug/DB00837/identifier/kegg-drug/
n9	http://linked.opendata.cz/resource/drugbank/drug/DB00837/identifier/drugbank/
n20	http://linked.opendata.cz/resource/mesh/concept/
n15	http://bio2rdf.org/drugbank:
n8	http://linked.opendata.cz/resource/drugbank/drug/DB00837/identifier/chemspider/
adms	http://www.w3.org/ns/adms#
n14	http://wifo5-03.informatik.uni-mannheim.de/drugbank/resource/drugs/
rdf	http://www.w3.org/1999/02/22-rdf-syntax-ns#
n17	http://linked.opendata.cz/resource/drugbank/drug/DB00837/identifier/wikipedia/
owl	http://www.w3.org/2002/07/owl#
n19	http://linked.opendata.cz/ontology/mesh/
n3	http://linked.opendata.cz/ontology/drugbank/
n16	http://linked.opendata.cz/resource/drugbank/drug/DB00837/identifier/pharmgkb/
n4	http://linked.opendata.cz/resource/drugbank/property/
xsdh	http://www.w3.org/2001/XMLSchema#
n6	http://linked.opendata.cz/resource/drugbank/drug/DB00837/identifier/pubchem-compound/
n11	http://linked.opendata.cz/resource/atc/
n10	http://linked.opendata.cz/ontology/sukl/drug/

Statements

Subject Item: n2:DB00837
rdf:type: n3:Drug
n3:description: Progabide is an analog and prodrug of gamma-aminobutyric acid. It is commonly used in the treatment of epilepsy. It has agonistic activity for both the GABAA and GABAB receptors. Progabide has been investigated for many diseases besides epilepsy, including Parkinson's disease, schizophrenia, clinical depression and anxiety disorder with varying success.
n3:generalReferences: # Bartholini G, Scatton B, Zivkovic B, Lloyd KG: GABA receptor agonists and extrapyramidal motor function: therapeutic implications for Parkinson's disease. Adv Neurol. 1987;45:79-83. "Pubmed":http://www.ncbi.nlm.nih.gov/pubmed/3030072
n3:group: approved investigational
n3:halfLife: 4 hours
n3:indication: Indicated for the treatment of epilepsy.
owl:sameAs: n14:DB00837 n15:DB00837
dcterms:title: Progabide
adms:identifier: n6:5361323 n7:46506568 n8:4514729 n9:DB00837 n16:PA164747990 n17:Progabide n18:D05621
n3:mechanismOfAction: Progabide binds to both GABAA and GABAB receptors located on the terminals of primary afferent fibers. Binding to GABAA results in an increased affinity of the GABA receptor for the amino acid, an augmented flux of chloride ions across the terminal membrane, and an increase in the amount of presynaptic inhibition. Activation of the GABAB receptors retards the influx of calcium ions into the terminals, thereby reducing the evoked release of excitatory amino acids and possibly other transmitters.
n3:synonym: Progabidum Halogabide Progabide Progabida
n3:proteinBinding: 95%
n19:hasConcept: n20:M0069177
n3:IUPAC-Name: n4:271B49E7-363D-11E5-9242-09173F13E4C5
n3:InChI: n4:271B49ED-363D-11E5-9242-09173F13E4C5
n3:Molecular-Formula: n4:271B49EC-363D-11E5-9242-09173F13E4C5
n3:Molecular-Weight: n4:271B49E9-363D-11E5-9242-09173F13E4C5
n3:Monoisotopic-Weight: n4:271B49EA-363D-11E5-9242-09173F13E4C5
n3:SMILES: n4:271B49EB-363D-11E5-9242-09173F13E4C5
n3:Water-Solubility: n4:271B49E5-363D-11E5-9242-09173F13E4C5 n4:271B49FD-363D-11E5-9242-09173F13E4C5
n3:logP: n4:271B49E6-363D-11E5-9242-09173F13E4C5 n4:271B49E3-363D-11E5-9242-09173F13E4C5 n4:271B49FF-363D-11E5-9242-09173F13E4C5
n3:logS: n4:271B49E4-363D-11E5-9242-09173F13E4C5
n10:hasATCCode: n11:N03AG05
n3:H-Bond-Acceptor-Count: n4:271B49F3-363D-11E5-9242-09173F13E4C5
n3:H-Bond-Donor-Count: n4:271B49F4-363D-11E5-9242-09173F13E4C5
n3:InChIKey: n4:271B49EE-363D-11E5-9242-09173F13E4C5
n3:Polar-Surface-Area--PSA-: n4:271B49EF-363D-11E5-9242-09173F13E4C5
n3:Polarizability: n4:271B49F1-363D-11E5-9242-09173F13E4C5
n3:Refractivity: n4:271B49F0-363D-11E5-9242-09173F13E4C5
n3:Rotatable-Bond-Count: n4:271B49F2-363D-11E5-9242-09173F13E4C5
n3:absorption: Well absorbed with a bioavailability of 60%
n3:affectedOrganism: Humans and other mammals
n3:casRegistryNumber: 62666-20-0
n3:category
n3:Bioavailability: n4:271B49F9-363D-11E5-9242-09173F13E4C5
n3:Ghose-Filter: n4:271B49FB-363D-11E5-9242-09173F13E4C5
n3:MDDR-Like-Rule: n4:271B49FC-363D-11E5-9242-09173F13E4C5
n3:Melting-Point: n4:271B49FE-363D-11E5-9242-09173F13E4C5
n3:Number-of-Rings: n4:271B49F8-363D-11E5-9242-09173F13E4C5
n3:Physiological-Charge: n4:271B49F7-363D-11E5-9242-09173F13E4C5
n3:Rule-of-Five: n4:271B49FA-363D-11E5-9242-09173F13E4C5
n3:Traditional-IUPAC-Name: n4:271B49E8-363D-11E5-9242-09173F13E4C5
n3:pKa--strongest-acidic-: n4:271B49F5-363D-11E5-9242-09173F13E4C5
n3:pKa--strongest-basic-: n4:271B49F6-363D-11E5-9242-09173F13E4C5